Skip to content

A Comparative Clinical Study of Gokshuradi guggulu and Pramehahara guggulu in the management of Madhumehjanya updrava (Diabetic Nephropathy)

Clinical evaluation of Gokshuradi Guggulu and Pramehahara Guggulu in the management of Madhumehjanya updrava (Diabetic Nephropathy) An open label Randomized Comparative Clinical Trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/03/024321
Enrollment
30
Registered
2020-03-27
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R801- Persistent proteinuria, unspecified

Interventions

Intervention1: Group B: In group B,15 patients will be given Pramehhahar guggulu in the dosage of 500 mg 2 vati thrice a day after meal with luke warm water for the duration of 60 days. Intervention2:

Sponsors

Institute for Post Graduate Teaching and Research in Ayurveda Jamnagar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Both freshly detected and previously diagnosed cases of Diabetic nephropathy. Patients with a clinical positive history of only type 2 DM having clinical features of Diabetic nephropathy like albuminuria, raised serum creatinine and blood urea will be included. Patients with microalbumin >=30 and Patients diagnosed with First and second grade of Diabetic nephropathy will be included. Patients with s.creatine >=1.4 and Patients with eGfr >=60 and

Exclusion criteria

Exclusion criteria: Patient aged below 18 years and above 65 years, pregnant ladies. Patients with type 1 DM will be excluded. Patients with macroalbumin that is >=300 mg/24 hour urine sample will be excluded. Patients with an eGFR (glomerular filtration rate) less than 60 ml/min/1.73m2. Patients with serum creatinine level above 5 mg/dl. Female patients having pregnancy, lactating or post-delivery period. Patients suffering from HIV, TB other infectious diseases, malignancies, major psychiatric problems or any other serious illnesses. Patients with uncontrolled blood pressure will be excluded.

Design outcomes

Primary

MeasureTime frame
Reduction in the level of urine micro albumin and marked improvement in kidney functionsTimepoint: 8 weeks

Secondary

MeasureTime frame
Relief in sign and symptoms of Diabetic Kidney Disease.Timepoint: 8 weeks

Countries

India

Contacts

Public ContactDr Alankruta Dave

Institute for Post Graduate Teaching and Research in Ayurveda Jamnagar.I

alankruta@yahoo.com9824171817

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026